of the HER family, except for HER2, undergo conformational changes that allow for dimerization, which is necessary for activation of the TK domain. HER2 does not have an identifi ed ligand and exists in a fi xed conformation r esembling the ligand-activated state of the other HER family receptors, allowing dimerization in the absence of ligand binding [3] . HER3 lacks a TK domain, so heterodimerization with HER2 or either ligand-bound HER1 or HER4 is necess ary for downstream signaling through this receptor. The normal function of HER2 is to form heterodimers with other activated members of the HER family, which initiate a cascade of downstream signaling through multiple intracellular pathways. As a result, cell-cycle activation, cell proliferation and increased cell survival through inhibition of apoptosis occur [4] .
HER2 gene amplifi cation occurs in 18-23% of breast cancers [5, 6] , and is associated with a worse prognosis and more aggressive behavior in both early and metastatic breast cancer [7] . Amplifi cation results in marked elevations of protein expression, giving rise to extensive HER2 homodimerization, which results in ligand-independent activation of the phospho inositide-3 kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK) downstream pathways. Activation of these critical pathways results in cell proliferation, cell-cycle progression and survival, and the sustained, inappropriate activation of these pathways play a central role in the behavior of these cancers. Heterodimerization of overexpressed HER2 After nonmelanoma skin cancer, breast cancer remains the most common cancer diagnosis among women in the USA. The annual incidence of breast cancer increased through 2001 but then began to decrease annually by 3% . Mortality from breast cancer has been declining by 2.2% since 1990, presumably owing to the broad acceptance of screening mammography and the improved effi cacy of treatments for early-stage disease [101] . Advances in understanding of molecular and cellular biology have accelerated the development of improved therapies by identifying critical pathways related to cell-cycle progression, proliferation and cell survival. Specifi c aberrations in these pathways have been identifi ed that play a critical role in the development of the malignant phenotype. One of the most signifi cant of these is the amplifi cation of the gene for the human epidermal growth factor receptor (HER)2 protein, a member of the HER family of cell surface receptors.
HER-receptor family
The HER family of transmembrane protein receptors consists of four related members: HER1 (also termed EGF receptor [EGFR]), HER2, HER3 and HER4, or ErbB-1, -2, -3 or -4, respectively [1, 2] . They share a common structural motif: an extracellular binding domain, a transmembrane lipophilic segment and an intracellular tyrosine kinase (TK) domain. Following ligand binding, the members REVIEW Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer Bushra Haq & Charles E Geyer † Amplifi cation of the human epidermal growth factor receptor 2 (HER2) gene occurs in 18-23% of invasive breast carcinomas and is associated with a worse prognosis. This novel transforming gene was identifi ed in 1985, and in 1987 HER2 amplifi cation was demonstrated to be central to the aggressive, malignant phenotype of these cancers and a signifi cant predictor of both time to relapse and overall survival. These observations led to the development of the fi rst monoclonal antibody targeting the extracellular domain of HER2, trastuzumab (Herceptin ® , Genentech and Hoffman LaRoche, Switzerland), which was approved by the US FDA for metastatic breast cancer in 1998. In 2005, results from four major trastuzumab adjuvant trials demonstrated a marked reduction in risk of recurrence, and trastuzumab is now an essential component of the adjuvant treatment of HER2-positive early breast cancer. Concerns regarding cardiac safety and mechanisms of resistance to trastuzumab remain important issues and are being addressed in ongoing research efforts.
Ligand-binding domain
Abnormal process of ligand-independent homodimerization and pathway activation with HER2 gene amplification and increased HER2 protein levels HER1 ligands TGF-α, EGF, Amp, β-cel, HB-EGF and Epi 
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protein with other HER family members may also contribute to the inappropriate activation of these pathways (FIGURE 1).
Trastuzumab in metastatic breast cancer
The fi rst successful therapy developed to specifically target HER2 gene amplifi cation was trastuzumab (Herceptin ® , Genentech and Hoffman LaRoche, Switzerland), a humanized monoclonal antibody directed against an epitope on the extracellular domain of HER2 [8] . Trastuzumab mono therapy demonstrated response rates of 26% as first-line therapy for HER2-positive metastatic breast cancer [9] , and 15% in patients previously treated with chemotherapy [10] . When combined as fi rst-line therapy with a number of different chemotherapeutic agents, trastuzumab has resulted in response rates ranging from 40-70% [11] [12] [13] . In the pivotal Phase III trial, which combined trastuzumab with doxorubicin plus cyclophosphamide (AC) or paclitaxel, 469 women with previously untreated metastatic breast cancer were randomly assigned to chemotherapy alone versus chemotherapy with trastuzumab. The addition of trastuzumab led to an improved response rate (50 vs 32%; p < 0.001), improved median duration of response (9.1 vs 6.1 months; p < 0.001), and prolonged overall survival (OS) (median 25.1 vs 20.3 months; p = 0.046) [11] .
Results of these trials led to the approval of trastuzumab for the treatment of HER2-positive metastatic breast cancer (TABLE 1) [102].
Trastuzumab & cardiac dysfunction in metastatic breast cancer trials
The most important adverse event in the pivotal Phase III trial of trastuzumab was cardiac d ysfunction. Asymptomatic or symptomatic Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer -REVIEW left ventricular dysfunction was identifi ed in 27% of patients who received AC plus trastuzumab, 8% of those who received AC alone, 13% of the group given paclitaxel and trastuzumab and 1% of those receiving paclitaxel alone. The rates of New York Heart Association (NYHA) Class III or IV symptomatic heart failure were 16, 3, 2 and 1%, respectively. Patients receiving p aclitaxel had previously received an a nthracycline as a component of their adjuvant therapy [11] .
While the inhibition of HER2 signaling is presumed to be the central mechanism of trastuzumab-related cardiotoxicity, the exact pathophysiologic mechanism is unknown.
A knockout mouse model with a cardiacrestricted, conditional HER2 deletion mutant developed dilated cardiomyopathy [14] and showed enhanced susceptibility to anthracycline-induced cardiotoxicity [15] . These and other data suggest that the inhibition of HER2 receptor-dependent myocyte survival pathways may increase susceptibility to heart failure follow ing the known cardiotoxicity associated with anthracycline treatment.
Randomized trials of adjuvant trastuzumab
Treatment for HER2-positive metastatic breast cancer has been greatly improved by the addition of HER2-targeted therapy, and some patients treated with trastuzumab remain free of progressive disease for years, even though most eventually succumb to their disease. Since HER2targeted therapy provided important benefi ts in the metastatic setting, clinical trials were developed to evaluate trastuzumab in the adjuvant setting. Many early-stage HER2-positive breast cancer patients can be treated successfully by surgery, chemotherapy, endocrine therapy and radiotherapy and, as such, incremental cardiotoxicity was a critical design issue in adjuvant trastuzumab trials. Since the rates of cardiac dysfunction that occurred in those who received concomitant anthracyclines and trastuzumab were unacceptable, adjuvant trials were designed to give anthracyclines and trastuzumab sequentially rather than concomitantly. One trial also evaluated an important nonanthracycline r egimen [16] .
Design of adjuvant trials of trastuzumab
The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of randomized t rials of polychemotherapy in early-stage breast cancer demonstrated that anthracycline-based regimens were superior to nonanthracyclinebased regimens with respect to recurrence (p = 0.00001) and breast cancer mortality (p < 0.00001) [17] . Retrospective data conducted on tumor specimens from a subset of patients from Cancer and Leukemia Group B (CALGB) trial 8541, which compared three dose levels (standard, moderate and low) of cyclophosphamide, doxorubicin and fl uorouracil (CAF) in 1572 women with node-positive breast cancer suggested that a benefi t from standard-dose CAF over lower-dose levels of CAF was limited to patients with HER2-positive tumors [18] . A recent meta-ana lysis of a series of retrospective studies of specimens from trials that showed the superiority of anthracycline-containing regimens relative to non-anthracycline regimens demonstrated that the incremental benefi ts of anthracyclines appeared to be limited to women with HER2-positive breast cancer. Among these patients (n = 1536) the hazard ratio (HR) was 0.71 (95% CI: 0.61-0.83; p < 0.001) for disease-free survival (DFS) and 0.73 (95% CI: 0.62-0.85; p < 0.001) for OS. No benefi t was apparent for anthracycline regimens for women with HER2-negative disease. The test for interaction between HER2 status and receipt of anthracyclines was signifi cant for both DFS (χ 2 = 13.7; p < 0.001) and OS (χ 2 = 12.6; p < 0.001) [19] .
The inclusion of anthracyclines in the chemo therapy regimens used in the a djuvant trastuzumab trials was an important issue because of the cardiotoxicity associated with [20, 21] and node-n egative (trial B-23) breast cancer [22] . Subsequent t rials conducted by CALGB (9344) [23] and the NSABP (trials B-27 and B-28) [24, 25] d emonstrated improved outcomes with the administration of paclitaxel or docetaxel for four cycles following AC. These sequential regi mens were c hosen as the c ontrol chemo therapy regimens in B-31, North Central Cancer Treatment Group (NCCTG) N9831 [26] , and Breast Cancer International Research Group (BCIRG) 006 [16] . In these t rials, patients completed AC before they received trastuzumab in c ombination with a taxane. It was thought that the sequential administration of the a nthracycline followed by trastuzumab would lower the risk of cardiotoxicity to a level that would be acceptable in the adjuvant s etting. The Herceptin Adjuvant (HERA) trial also used the sequential approach by having all chemotherapy completed before random assignment to 1 or 2 years of t rastuzumab or observation.
NSABP B-31, NCCTG N9831, BCIRG 006 & the HERA trial
The NSABP B-31 trial compared four cycles of AC followed by four cycles every 3 weeks of paclitaxel (AC→P, arm 1) with AC→P plus 52 weeks of trastuzumab beginning with the fi rst cycle of paclitaxel (AC→PH→H, arm 2). The NCCTG N8931 trial was a three-arm study that compared four cycles of AC followed by 12 weekly doses of paclitaxel (AC→WP, arm A) with AC→WP followed by 52 weeks of trastuzumab beginning after paclitaxel (AC→WP→H, arm B) and with AC→WP plus 52 weeks of trastuzumab beginning with the fi rst week of paclitaxel (AC→WPH→H, arm C). Since arms 1 and 2 of B-31 were similar to arms A and C of N9831, the studies were amended before any interim analyses to provide for a joint statistical ana lysis comparing the control arms with the concurrent arms of the two studies (FIGURE 2). The BCIRG 006 trial employed four cycles of AC followed by four cycles of docetaxel (AC→T) as the control chemotherapy regimen. One investigational arm initiated 52 weeks of trastuzumab concurrently with docetaxel (AC→TH→H). The study included a third arm evaluating a novel nonanthracycline regimen consisting of six cycles of carboplatin plus docetaxel initiated concurrently with 52 weeks of trastuzumab (TCH→H) [25] . The regimen was based on preclinical observations of synergy between platinum-based chemotherapy and trastuzumab and supported by data from t rials conducted in women with metastatic breast cancer [27, 28] .
The HERA trial required eligible patients to have received at least four cycles of neo adjuvant or adjuvant chemotherapy from a list of approved regimens before entry and random assignment. Most patients received an a nthracycline-based chemotherapy regimen (94%), while a minority (26%) received a taxane [29] .
Cardiac eligibility criteria & cardiac monitoring
All of the trials were limited to patients in good health without pre-existing cardiac disease. B-31 and N9831 required entry left ventricular ejection fraction (LVEF) to be in the n ormal range for the institution [26] . BCIRG 006 required entry LVEF to be 50% or greater [16] . HERA required patients to have a LVEF of 55% or greater following chemotherapy and radiotherapy [29] . Similar guidelines for the initiation and continuation of trastuzumab were employed, with mandatory discontinuation of trastuzumab in the event of confi rmed substantive asymptomatic declines in LVEF or symptomatic cardiac dysfunction.
NSABP B-31 and NCCTG N9831 used the same end point for severe cardiac toxicity, referred to as a cardiac event (CE) [26] . A CE was defi ned as confi rmed congestive heart failure (CHF) with NYHA Class III or IV symptoms or defi nite or probable cardiac death. The defi nition of a CE in BCIRG 006 was broader than that in B-31 and N9831 [16] . Any symptomatic left ventricular dysfunction (NHYA Class II, III or IV symptoms), grade 3 or 4 cardiac ischemia/ infarction, grade 3 or 4 cardiac arrhythmias, and cardiac-related deaths were all included in the end point in BCIRG 006.
The HERA trial also employed different defi nitions for cardiac toxicities [29] . Cardiac death was defi ned as death defi nitely due to heart failure, myocardial infarction or documented arrhythmia, or sudden unexpected death within 24 h of a defi nite or probable CE. Severe CHF was defi ned as a patient having NYHA class III or IV symptoms, confi rmed by a cardiologist, with a signifi cant LVEF decline. A signifi cant LVEF decline was defi ned as an 
BCIRG-006
The fi rst interim ana lysis of BCIRG 006 was conducted with a median follow-up of 23 months. The HR for DFS events of AC→TH→H relative to AC→T was 0.49 (95% CI: 0.37-0.65; p < 0.0001) and 0.61 (95% CI: 0.47-0.79; p = 0.0003) for TCH→H relative to AC→T [16] .
There were an insuffi cient number of deaths to analyze survival at the initial report. A follow-up ana lysis was conducted with a median followup of 36 months [31] . The HR for DFS events of AC→TH→H relative to AC→T was 0.61 (95% CI: 0.48-0.76; p < 0.0001) and 0.67 (95% CI: 0.54-0.83; p = 0.0002) for TCH→H relative to AC→T. Survival was improved with a HR for death of 0.59 (95% CI: 0.42-0.85; p = 0.004) with AC→TH→H relative to AC→T and 0.66 (95% CI: 0.47-0.93; p = 0.017) with TCH→H relative to AC→TH→H. The 4-year DFS was improved from 77% in the control arm to 83% with AC→TH→H and to 82% with TCH→H. No statistical difference was evident between the two investigational arms, but the study was underpowered for this comparison. However, the CI around the point estimates for the DFS HRs overlapped widely, suggesting similar clinical activity.
HERA trial
The interim ana lysis of the HERA trial was conducted with 1 year of median follow-up [29] .
The unadjusted HR for a DFS event in the ). An improvement in OS was also demonstrated with an un adjusted HR for the risk of death of 0.66 (95% CI: 0.47-0.91; p = 0.0115). Results comparing 1 versus 2 years of trastuzumab have not been reported.
Cardiac toxicity data from adjuvant trials NSABP B-31
A formal cardiac safety ana lysis with 3 years of median follow-up was reported shortly after the joint effi cacy ana lysis was published [33] . The cumulative incidence of CEs was 4.1% in the trastuzumab-treated patients versus 0.8% in control patients, giving an absolute difference of 3.3% (95% CI: 1.7-4.9). Trastuzumab was discontinued early owing to cardiac effects (asympto matic decline in LVEF, symptoms of cardiac dysfunction or other cardiac symptoms) in 19% of patients. Approximately 14% of these were due to confi rmed, substantive, asymptomatic declines in LVEF. Potential predictors for an increased risk of a CE were also evaluated. Age of over 50 years (p = 0.03), need for hypertension medication at entry (p = 0.07), and baseline LVEF below 55% (p = 0.0001) were predictive. Women aged younger than 50 years had a 2% risk of developing a CE, while women aged 50 years and older had a risk of 5.3-5.4%. A need for hypertension medication resulted in a risk of 5.2%. Women with a baseline LVEF within the normal range but less than 55% had a 3-year cumulative incidence of 14.5% for a CE. Other potential risk factors such as left-sided radiation therapy, smoking history, family history, diabetes or hyper lipidemia were not predictive. A 5-year update of cardiac dysfunction in NSABP-31 was recently reported, demonstrating that the cumulative incidence of CEs in this study remained unchanged at 3.9% [34] .
NCCTG N9831
The 3-year cumulative incidence of CHF was 0.3% in the control arm and 3.3% in the concurrent trastuzumab arm [35] . Factors a ssociated with an increased risk of a CE with trastuzumab were evaluated. Women aged 60 years or younger had a risk of 6.6%, women aged 50-59 years had a 2.8% risk, and women younger than 50 years had a 2.1% risk (p < 0.003). Prior or current use of anti hypertensive agents increased the risk to 6.6% (p = 0.005). Baseline LVEF less than 55% also increased the risk to 5.6% (p = 0.033), which was less pronounced than what was reported in the B-31 trial. No other risk factors were identifi ed. Overall, the risk factor ana lysis of N9831 supports the fi ndings of B-31.
BCIRG 006
The defi nition of a CE in BCIRG 006 was broader than that in B-31 and N9831. At the time of the initial effi cacy report, the rate of CE by the 006 criteria was 0.95% (95% CI: 0.46-1.74) with AC→T compared with 2.34% (95% CI: 1.52-3.44) with AC→TH→H (p = 0.016), and 1.33% (95% CI: 0.72-2.21) with TCH→H (p = 0.54) [16] . At the updated effi cacy ana lysis, cardiac toxicity was reported using criteria similar to those used in B-31 and N9831 [31] . No cardiac deaths Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer -REVIEW had occurred on BCIRG 006, so the number of patients with symptomatic LV dysfunction was 4/1050 (0.38%) with AC→T, 20/1068 (1.87%) with AC→TH→H, and 4/1056 (0.38%) with TCH→H. The difference between the rates in the trastuzumab arms was statistically significant (p = 0.0015). The percentages of patients with a relative decline from a baseline of 10% or over were 10, 18 and 9%, respectively, for the three regimens.
HERA
The HERA trial had a number of important design differences from the other large t rials [29] .
Patients had to complete chemotherapy and radiotherapy before random assignment and had to have a postchemotherapy LVEF of 55% or over. With a median follow-up of 12 months, the cumulative risk of severe CHF was 0.6% in the trastuzumab arm and 0% in the observation arm [36] ; this corresponds to the defi nition of a CE in both B-31 and N9831. The rate of symptomatic CHF was 2.15% in the trastuzumab arm and 0.12% in the observation arm; this c orresponds to the defi nition of c ardiac dysfunction in BCIRG 006. Patients with a screening LVEF of 55-59% had a signifi cantly higher incidence of one of the HERA c ardiac end points of 6.90 versus 2.72% for higher LVEF values.
Patients with potential risk f actors for hypertension (e.g., aged over 60 years, smoking history, diabetes or hypothyroidism) also had a nonsignifi cant trend toward a higher incidence.
Future perspective
Effi cacy and safety results from these four large adjuvant trials have established trastuzumab as an essential component of systemic therapy for operable, HER2-positive breast cancer. However, questions regarding the optimal use of trastuzumab remain. Perhaps the most important of these involves the impact that the inclusion of anthracyclines has on the efficacy and cardiac toxicity of trastuzumab when used in combination with chemotherapy in the adjuvant setting. The decision to complete the anthracycline-based portion of chemotherapy before the initiation of trastuzumab was successful in keeping the rate of severe cardiac toxicity low enough for the adjuvant setting, in view of the marked reduction in risk for recurrence and death with the introduction of trastuzumab. However, the data from BCIRG 006 clearly demonstrate that the risk of cardiotoxicity with trastuzumab in the absence of anthracyclines (TCH→H) is negligible and the regimen has substantial activity [16, 31] . Unfortunately, BCIRG 006 was not powered to determine small differences in effi cacy, so uncertainty remains regarding the activity of TCH→H relative to AC→TH→H. While the confi dence intervals around the point estimates overlapped widely, the HRs for improved DFS and OS for AC→TH→H relative to control (AC→T) have been slightly better numerically than for TCH→H, relative to the same control.
It is unlikely that a study adequately powered to address this question will ever be conducted, or that additional follow-up will provide suffi cient events to demonstrate small differences, given the effi cacy of both trastuzumab regimens. Concordant data from NSABP B-31 and NCCTG N9831 clearly identify patients with an elevated degree of risk for severe cardiac toxicity associated with the sequential AC-followedby-paclitaxel-plus-trastuzumab regimens [33, 34] . Women aged over 55-60 years, those on antihypertensive medication, and particularly those with LVEF values below 55% appear to have a degree of risk that does not justify treatment with an anthracycline-containing regimen, given the activity and negligible cardiac risk with TCH→H. Women without these risk factors were still at increased risk for severe CEs with sequential regimens relative to TCH→H and should be presented with the effi cacy and safety data from both approaches to allow them to make an informed risk-benefit decision regarding a djuvant systemic therapy.
Other unanswered questions will ultimately be addressed with additional follow-up of N9831 and HERA. N9831 had two investigational arms that only differed by the timing of the initiation of trastuzumab; the unreported arm (arm B) from the study initiated trastuzumab after the completion of paclitaxel; the other investigational arm (arm C), combined with NSABP B-31 in the joint effi cacy analysis, began trastuzumab concurrently with paclitaxel. After additional follow-up, both arms will be compared with the control arm, and the study is reported to be suffi ciently powered to detect clinically relevant differences in effi cacy end points between the two approaches. The comparison of 1 year of trastuzumab with the unreported arm of HERA, in which patients received 2 years of trastuzumab, will provide important information regarding duration when trastuzumab is initiated following completion of chemotherapy. The FinHer study, which randomized 1010 women with early breast cancer to receive three cycles of 
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either docetaxel or vinorelbine followed by three cycles of fl uorouracil, epirubicin and cyclophosphamide (FEC), included a subset of 232 patients with HER2-positive breast cancer who were also randomized to receive trastuzumab for 9 weeks with their docetaxel or vinorelbine. Trastuzumab, administered for this brief period concurrently with chemotherapy, was found to improve recurrence-free survival (HR: 0.42; 95% CI: 0.21-0.83; p = 0.01), with a trend toward improved OS (HR: 0.41; 95% CI: 0.16-1.08; p = 0.07) [37] . These results suggest that a shorter duration of trastuzumab might be suffi cient when it is administered concurrently with chemotherapy. A shorter duration of trastuzumab could decrease the incidence of cardiac toxicity and would substantially lower the considerable costs relative to a full year of therapy. However, the results need to be verifi ed by larger trials, and an o ngoing French study is comparing 6-12 months of trastuzumab [103] .
In spite of the remarkable improvement in outcome for women with early-stage HER2-positive breast cancer, some of these women still develop recurrence [29] . The second generation of adjuvant trials for HER2-positive breast cancer is evaluating methods to overcome the resistance demonstrated in patients who develop recurrent disease. Amplifi cation of HER2 is associated with the production of VEGF, which promotes angiogenesis and contributes to the malignant phenotype of HER2-amplifi ed breast cancer [38] . Preclinical models [39] and data from a Phase I/II trial in which trastuzumab was combined with another monoclonal antibody that binds to VEGF [40, 41] , bevacizumab, indicate that important potential synergy exists for the simultaneous inhibition of Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer -REVIEW to receive chemotherapy with trastuzumab or chemotherapy with trastuzumab plus bevacizumab. The two trial groups and some of the international investigators are using TCH→H as the control regimen in the trial. Other international investigators are using a regimen of docetaxel plus trastuzumab for three cycles followed by a regimen of FEC for three cycles followed by completion of 52 weeks of trastuzumab as their control regimen. In both investigational arms, bevacizumab is administered concurrently with trastuzumab.
The Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (ALTTO) trial (FIGURE 3) [105] is another international trial being conducted jointly by the Breast International Group and the North American Breast Cancer Intergroup to evaluate the potential role of lapatinib (Tykerb ® , GlaxoSmithKline, UK), a smallmolecule, dual TK inhibitor of HER2 and HER1 (EGFR) [42] in the adjuvant therapy of HER2positive breast cancer. Lapatinib plus capecitabine has been shown to be superior to capecitabine alone in women with heavily pretreated m etastatic breast cancer that had progressed following therapy with regimens containing trastuzumab, an anthra cycline and a taxane [43] . All patients in ALTTO receive an anthracycline-based chemotherapy r egimen and then begin HER2-targeted therapy. Paclitaxel may be administered concurrently with targeted therapy at the investigator's d iscretion. Patients are randomized to receive one of four t argeted therapy regimens for 1 year: trastuzumab; lapatinib; trastuzumab for 3 months f ollowed by lapatinib for 9 months; or trastuzumab in c ombination with lapatinib.
Understanding and overcoming trastuzumab resistance is a major focus of academia and the pharmaceutical industry. Lapatinib was the fi rst drug developed and approved to address this issue. Other agents such as pan-HER inhibitors [44, 45] , heat-shock protein inhibitors [46] , insulin-like growth factor (IGF) inhibitors [47] , and other HER2-targeted mono clonal antibodies, such as pertuzumab [48] [49] [50] [51] , are being developed and evaluated in patients with metastatic HER2-positive breast cancer. The wealth of potential agents to overcome trastuzumab resistance offers hope that effective treatment will ultimately be available for all women who develop HER2-positive breast cancer.
Financial & competing interests disclosure
The authors have no relevant affi liations or fi nancial involvement with any organization or entity with a fi nancial interest in or fi nancial confl ict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Executive summary

Human epidermal growth factor receptor family
Human epidermal growth factor receptor (HER) family of transmembrane proteins consists of four • related members: HER1, HER2, HER3 and HER4. HER2 • gene amplifi cation occurs in 18-23% of invasive breast carcinomas and is associated with a worse prognosis and more aggressive behavior. Ligand-independent activation of downstream pathways plays a central role in the behavior of • these cancers.
Trastuzumab in metastatic breast cancer
Trastuzumab is a monoclonal antibody directed against an epitope on the extracellular domain • of HER2. It is the fi rst successful targeted therapy developed specifi cally to treat HER2-positive breast cancer. • Trastuzumab monotherapy has been shown to be active as fi rst-line as well as second-line therapy in • metastatic HER2-positive breast cancer. Combinations of trastuzumab with various chemotherapeutic agents as fi rst-line therapy resulted • in response rates ranging from 40 to 70%.
Trastuzumab & cardiac function
An important adverse effect of trastuzumab in the pivotal Phase III trial was cardiac dysfunction. • Incidence of cardiotoxicity was higher in patients who received anthracycline and • trastuzumab concurrently. The exact pathophysiologic mechanism of trastuzumab-related cardiotoxicity is unknown. • Preclinical data suggest that inhibition of HER2 receptor-dependent myocyte survival pathways may • increase susceptibility to heart failure following the known cardiotoxicity associated with anthracycline treatment.
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Executive summary
Design of adjuvant trastuzumab trials
Since the majority of women with early-stage breast cancer can be effectively treated with a • combination of locoregional therapy (surgery and radiation) and systemic therapy (chemotherapy and endocrine therapy), trastuzumab-related cardiotoxicity was a major concern of the investigators designing the adjuvant trastuzumab trials. Adjuvant trials were designed to give trastuzumab sequentially after anthracycline-based • chemotherapy regimens rather than concomitantly because of the results in the metastatic setting that demonstrated higher rates of cardiotoxicity with concomitant anthracycline and trastuzumab therapy. The BCIRG 006 trial included a nonanthracycline regimen. • All four major adjuvant trastuzumab trials defi ned cardiac eligibility criteria as well as protocols for • cardiac monitoring. 
Effi cacy results of adjuvant trastuzumab trials
Future perspective
Current data support the use of adjuvant regimens that combine trastuzumab with chemotherapy; • however, many questions regarding the optimal use of trastuzumab remain unanswered. Based on the BCIRG 006 data, which demonstrated that TCH had similar effi cacy but negligible • cardiotoxicity compared with the anthracycline-containing arm, TCH should be offered to all women with HER2-positive breast cancer to allow them to make an informed risk-benefi t decision regarding adjuvant systemic therapy. Additional follow-up data of N9831 will address the question of whether sequential therapy of • trastuzumab following paclitaxel differs from the combined use of trastuzumab with paclitaxel. et al.: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J. Clin. Oncol. 23, 7811-7819 (2005) . N. Engl. J. Med. 354, 809-820 (2006) . 
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